Gastric pentadecapeptide
BPC 157 was administered (initial single or continuous administration) into rats either intragastrically or intramuscularly before (induced acute
gastric ulcer) or after (induced chronic
gastric ulcer) the applications of inducing agents, and each animal was sacrificed to observe the protective effects of
BPC 157 on
gastric ulcers.
RESULTS: Both intramuscular (im) and intragastric (ig) administration of
BPC 157 could apparently reduce the
ulcer area and accelerate the healing of induced
ulcer in different models and the effect of im administered
BPC 157 was better than that of ig. The rats treated with higher dosages (400 ng/kg, 800 ng/kg) of
BPC 157 (im and ig) showed significantly less lesion (P<0.01 vs
excipient or saline control), the inhibition ratio of
ulcer formation varied between 45.7% and 65.6%, from all measurements except 400 ng/kg
BPC 157 in pylorus
ligation induced model (P<0.05), in which the inhibition rate was 54.2%. When im administered (800 ng/kg
BPC 157) in three models, the inhibition ratio of
ulcer formation was 65.5%, 65.6% and 59.9%, respectively, which was better than that of
famotidine (its inhibition rate was 60.8%, 57.2% and 34.3%, respectively). Continuous application of
BPC 157 (in chronic
acetate induced
gastric ulcer) could accelerate rebuilding of glandular epithelium and formation of granulation tissue (P<0.05 at 200 ng/kg and P<0.01 at 400 ng/kg and 800 ng/kg vs
excipient or saline control).
CONCLUSION: Both im and ig administered gastric pentadecapeptide
BPC 157 can apparently ameliorate acute
gastric ulcer in rats and antagonize the protracted effect of
acetate challenge on chronic
ulcer. The effect of im administration of
BPC 157 is better than that of ig, and the effective dosage of the former is lower than that of the latter.